0IFK.L

Editas Medicine, Inc. [0IFK.L] Stock Forecast

Q: What is Editas Medicine, Inc. stock symbol ?

Editas Medicine, Inc. is a US stock, located in Cambridge of Ma and trading under the symbol 0IFK.L

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

0IFK.L Stock Summary

Earnings have grown 296.32% per last year.

EPS has been increasing for the past 3 quarters (Quarter statements)

0IFK.L has more than 6 years of cash runway (83 months)

Earnings are expected to fall -100% next year

Profit margins (-7.93%) are lower than the previous year (-1.96%)

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

0IFK.L

Top 10 Correlated Stocks

0IFK.L

In the News

0IFK.L Financial details

Company Rating

Sell

Market Cap

516.25M

Income

-153.22M

Revenue

78.12M

Book val./share

4.27

Cash/share

3.95

Dividend

Dividend %

Employees

265

Optionable

Shortable

Yes

Earnings

03 May 2024

P/E

-3.86

Forward P/E

PEG

1.07

P/S

30.6

P/B

2.09

P/C

1.44

P/FCF

-4.82

Quick Ratio

6.01

Current Ratio

6.12

Debt / Equity

0.03

LT Debt / Equity

EPS (TTM)

-2.05

EPS next Y

EPS next Q

EPS this Y

-37.07%

EPS next Y

EPS next 5Y

EPS last 5Y

-5.5%

Revenue last 5Y

30.64%

Revenue Q/Q

1025.36%

EPS Q/Q

-58.18%

SMA20

-24.47%

SMA50

-13.36%

SMA100

-27.87%

Inst Own

Inst Trans

ROA

-39%

ROE

-54%

ROC

-0.47%

Gross Margin

-295%

Oper. Margin

-848%

Profit Margin

-793%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

6.07-11.79

52W High

-48.18%

52W Low

-5%

RSI

25.77

Rel Volume

0.18

Avg Volume

5.91K

Volume

1.05K

Perf Week

-15.68%

Perf Month

-43.68%

Perf Quarter

-9.24%

Perf Half Y

-21.7%

Beta

2.018

Volatility

0.39%, 0.99%

Prev Close

-4.2%

Price

5.7

Change

-3.39%

0IFK.L Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.41	1.55	0.38	0.29	1.03
Net income per share	-2.68	-1.98	-2.85	-3.21	-2.02
Operating cash flow per share	-0.81	-3.07	-2.42	-2.58	-1.74
Free cash flow per share	-0.94	-3.19	-2.54	-2.64	-1.8
Cash per share	9.15	6.86	7.39	5.01	4.25
Book value per share	5.25	6.72	8.19	5.25	4.6
Tangible book value per share	5.25	6.72	8.19	5.25	4.6
Share holders equity per share	5.25	6.72	8.19	5.25	4.6
Interest debt per share	0.12	0.12	0.15	0.16	0.16
Market cap	993.02M	1.16B	1.34B	591.55M	780.17M
Enterprise value	783.92M	1.05B	1.17B	493.97M	693.05M
P/E ratio	-7.42	-10.04	-6.98	-2.68	-5.09
Price to sales ratio	48.37	12.83	52.59	30.01	9.99
POCF ratio	-24.42	-6.47	-8.2	-3.34	-5.9
PFCF ratio	-21.2	-6.23	-7.82	-3.26	-5.7
P/B Ratio	3.78	2.96	2.43	1.64	2.23
PTB ratio	3.78	2.96	2.43	1.64	2.23
EV to sales	38.18	11.58	45.66	25.06	8.87
Enterprise value over EBITDA	-5.68	-8.03	-6.2	-2.25	-4.25
EV to operating cash flow	-19.28	-5.84	-7.12	-2.79	-5.24
EV to free cash flow	-16.74	-5.62	-6.79	-2.72	-5.06
Earnings yield	-0.13	-0.1	-0.14	-0.37	-0.2
Free cash flow yield	-0.05	-0.16	-0.13	-0.31	-0.18
Debt to equity	0.02	0.02	0.02	0.03	0.03
Debt to assets	0.01	0.01	0.02	0.02	0.02
Net debt to EBITDA	1.51	0.87	0.94	0.44	0.53
Current ratio	7.74	7.2	10.82	5.94	5.39
Interest coverage	0	0	0	0	0
Income quality	0.3	1.55	0.85	0.8	0.86
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	3.14	0.74	2.98	3.59	0
Research and developement to revenue	4.58	1.7	5.38	8.55	2.2
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.15	0.04	0.05	0.02	0.04
Capex to revenue	-0.3	-0.08	-0.31	-0.21	-0.06
Capex to depreciation	-2.18	-1.81	-1.58	-0.65	-0.78
Stock based compensation to revenue	1.33	0.26	1.7	1.49	0
Graham number	17.78	17.29	22.9	19.48	14.44
ROIC	-0.48	-0.32	-0.33	-0.56	-0.44
Return on tangible assets	-0.26	-0.2	-0.28	-0.43	-0.31
Graham Net	4.22	3.88	5.56	2.83	2.38
Working capital	403.88M	360.88M	460.43M	296.64M	277.61M
Tangible asset value	262.44M	393.59M	553.64M	360.68M	349.1M
Net current asset value	217.4M	240.07M	383.47M	203.11M	190.77M
Invested capital	0.02	0.02	0.02	0.03	0.03
Average receivables	224K	3.23M	3.16M	2.71M	7.67M
Average payables	5.59M	6.13M	5.73M	7.28M	8.89M
Average inventory	0.5	0.5	1	0.5	0
Days sales outstanding	7.43	24.33	3.82	95.27	47.59
Days payables outstanding	22.01	14.8	364.78	547.82	497.72
Days of inventory on hand	0	0	0	0	0
Receivables turnover	49.12	15	95.67	3.83	7.67
Payables turnover	16.58	24.66	1	0.67	0.73
Inventory turnover	0	158M	5.05M	0	0
ROE	-0.51	-0.29	-0.35	-0.61	-0.44
Capex per share	-0.12	-0.12	-0.12	-0.06	-0.06

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.1	0.14	0.04	0.07	0.73
Net income per share	-0.88	-0.71	-0.56	-0.55	-0.23
Operating cash flow per share	-0.61	-0.52	-0.54	-0.43	-0.27
Free cash flow per share	-0.62	-0.55	-0.56	-0.44	-0.29
Cash per share	5	4.62	6.05	4.28	3.95
Book value per share	5.24	4.61	5.6	4.41	4.27
Tangible book value per share	5.24	4.61	5.6	4.41	4.27
Share holders equity per share	5.24	4.61	5.6	4.41	4.27
Interest debt per share	0.16	0.12	0.14	0.12	0.15
Market cap	592.65M	504.7M	591M	636.04M	839.17M
Enterprise value	495.08M	412.81M	407.37M	588.11M	752.05M
P/E ratio	-2.44	-2.57	-3.67	-3.53	-11.12
Price to sales ratio	90.68	51.23	204.71	119.2	13.97
POCF ratio	-14.02	-14.11	-15.27	-17.94	-37.73
PFCF ratio	-13.82	-13.42	-14.76	-17.82	-35.64
P/B Ratio	1.64	1.59	1.48	1.76	2.4
PTB ratio	1.64	1.59	1.48	1.76	2.4
EV to sales	75.75	41.91	141.1	110.22	12.52
Enterprise value over EBITDA	-8	-8.35	-9.57	-12.09	-33.43
EV to operating cash flow	-11.71	-11.54	-10.52	-16.59	-33.82
EV to free cash flow	-11.54	-10.98	-10.17	-16.47	-31.94
Earnings yield	-0.1	-0.1	-0.07	-0.07	-0.02
Free cash flow yield	-0.07	-0.07	-0.07	-0.06	-0.03
Debt to equity	0.03	0.03	0.03	0.03	0.03
Debt to assets	0.02	0.02	0.02	0.02	0.02
Net debt to EBITDA	1.58	1.86	4.32	0.99	3.87
Current ratio	5.94	5.68	8.09	6.12	5.39
Interest coverage	0	0	0	0	0
Income quality	0.7	0.73	0.96	0.79	1.18
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.75	2.34	5.96	2.81	0
Research and developement to revenue	7.71	3.68	9.78	7.31	1.13
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.05	0.03	0.01	0.06
Capex to revenue	-0.1	-0.19	-0.46	-0.04	-0.02
Capex to depreciation	-0.4	-1.19	-0.87	-0.16	-0.89
Stock based compensation to revenue	0.82	0.46	1.81	0.89	0
Graham number	10.21	8.59	8.44	7.4	4.71
ROIC	-0.16	-0.14	-0.1	-0.13	-0.06
Return on tangible assets	-0.12	-0.11	-0.07	-0.09	-0.04
Graham Net	2.83	2.5	4.09	2.54	2.21
Working capital	296.64M	267.3M	386.47M	300M	277.61M
Tangible asset value	360.68M	317.47M	399.92M	360.46M	349.1M
Net current asset value	203.11M	177.83M	298.94M	214.42M	190.77M
Invested capital	0.03	0.03	0.03	0.03	0.03
Average receivables	2.63M	2.69M	1.26M	2.35M	6.3M
Average payables	8.17M	9.28M	8.56M	9.24M	9.34M
Average inventory	0	0	0.5	0.5	0
Days sales outstanding	70.85	2.21	71.26	40.85	15.27
Days payables outstanding	542.8	527.35	471.39	618.88	507.65
Days of inventory on hand	0	0	0	0	0
Receivables turnover	1.27	40.71	1.26	2.2	5.89
Payables turnover	0.17	0.17	0.19	0.15	0.18
Inventory turnover	0	0	1.54M	0	0
ROE	-0.17	-0.15	-0.1	-0.12	-0.05
Capex per share	-0.01	-0.03	-0.02	0	-0.02

0IFK.L Frequently Asked Questions

What is Editas Medicine, Inc. stock symbol ?

Editas Medicine, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol 0IFK.L

What is Editas Medicine, Inc. stock quote today ?

Editas Medicine, Inc. stock price is $5.7 today.

Is Editas Medicine, Inc. stock public?

Yes, Editas Medicine, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 5.91K
Market Capitalization 516.25M
Employee 265
CEO Dr. Gilmore O'Neill M.D.
Headquarters Cambridge,MA,US
IPO Date 2018-01-29
Website https://www.editasmedicine.com

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.